These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 28687111)
1. Emerging Therapies in Hereditary Angioedema. Chen M; Riedl MA Immunol Allergy Clin North Am; 2017 Aug; 37(3):585-595. PubMed ID: 28687111 [TBL] [Abstract][Full Text] [Related]
2. Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment. Magerl M; Germenis AE; Maas C; Maurer M Immunol Allergy Clin North Am; 2017 Aug; 37(3):571-584. PubMed ID: 28687110 [TBL] [Abstract][Full Text] [Related]
3. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent. Kaplan AP; Joseph K Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087 [TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. Kaplan AP; Joseph K Immunol Allergy Clin North Am; 2017 Aug; 37(3):513-525. PubMed ID: 28687106 [TBL] [Abstract][Full Text] [Related]
5. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Zeerleder S; Levi M Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196 [TBL] [Abstract][Full Text] [Related]
6. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. de Maat S; Björkqvist J; Suffritti C; Wiesenekker CP; Nagtegaal W; Koekman A; van Dooremalen S; Pasterkamp G; de Groot PG; Cicardi M; Renné T; Maas C J Allergy Clin Immunol; 2016 Nov; 138(5):1414-1423.e9. PubMed ID: 27130860 [TBL] [Abstract][Full Text] [Related]
7. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Kaplan AP; Joseph K Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213 [TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Therapeutics in Hereditary Angioedema. Do T; Riedl MA Immunol Allergy Clin North Am; 2024 Aug; 44(3):561-576. PubMed ID: 38937016 [TBL] [Abstract][Full Text] [Related]
16. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Riedl M Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830 [TBL] [Abstract][Full Text] [Related]
17. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. Joseph K; Tholanikunnel BG; Wolf B; Bork K; Kaplan AP J Allergy Clin Immunol; 2016 Jun; 137(6):1822-1829.e1. PubMed ID: 26395818 [TBL] [Abstract][Full Text] [Related]
19. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780 [TBL] [Abstract][Full Text] [Related]
20. Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema. Cicardi M; Zanichelli A; Suffritti C; Wu MA; Machnig T; De Silvestri A; Regazzi M; Tinelli C J Allergy Clin Immunol; 2017 Jun; 139(6):2005-2007.e1. PubMed ID: 28025012 [No Abstract] [Full Text] [Related] [Next] [New Search]